Anti-CD20 monoclonal antibodies: reviewing a revolution - PMC
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice.
Next-generation anti-CD20 monoclonal antibodies in …
Anti-CD20 monoclonal antibodies (mAbs) are used to achieve B cell depletion, and were initially developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
CD20 - Wikipedia
Thus, anti-CD20 monoclonal antibodies (mAbs) play a crucial role in the management of B cell malignancies as well as some inflammatory and autoimmune diseases. The first anti-CD20 mAb approved by FDA in 1997 was Rituximab , defining a new epoch in hematooncology .
Anti-CD20 therapies for multiple sclerosis: current status and …
We summarize the rationale regarding the use of anti-CD20 therapies and the results of the main randomized controlled trials and observational studies investigating the efficacy and safety profile of rituximab, ocrelizumab, ofatumumab and ublituximab.
Anti-CD20 treatment for B-cell malignancies: current status
Introduction: The introduction of anti-CD20 monoclonal antibody therapy with rituximab in the 1990s greatly improved outcomes for patients with B-cell malignancies.
Rituximab, an Anti-CD20 Monoclonal Antibody: History and …
Rituximab, chimeric anti-human CD20, is approved for treatment of B-cell lymphoma in adults. It is being used experimentally in other various immune-related diseases such as immune thrombocytopenic purpura, systemic lupus erythematosus, myasthenia …
Efficacy and safety of new anti-CD20 monoclonal antibodies …
2021年2月5日 · Rituximab combined with chemotherapy is the first-line induction therapy of CD20 positive B-cell non-Hodgkin lymphomas (CD20 + B-NHL). Recently new anti-CD20 monoclonal antibodies (mAbs)...
Long-term treatment with anti-CD20 monoclonal antibodies is …
2022年6月9日 · Due to the low passage of mAbs over the blood–brain barrier, the mechanism of action from anti-CD20 therapies is mainly in the periphery, giving rise to undetectable levels of B-cells in blood.
Key characteristics of anti-CD20 monoclonal antibodies and …
2023年10月31日 · Rituximab, ocrelizumab, ofatumumab, ublituximab and BCD-132 are anti-CD20 therapies that are either undergoing clinical development, or have been approved, for the treatment of MS.
Full article: Anti-CD20 treatment for B-cell malignancies: current ...
Novel anti-CD20 mAbs have structural and pharmacodynamic characteristics that distinguish them from rituximab. In this section, we examine these characteristics and their mechanistic consequences in preparation for later discussion of their clinical consequences.